JUN LI/iStock via Getty Images The World Health Organization informed on Friday that Gavi, Unicef, and its other partners can start purchasing mpox vaccines before the global health agency approves them amid an ongoing global outbreak, Reuters reported. Gavi, a Geneva-based NGO that aims to improve vaccine access in low-income countries, and similar organizations can only start purchasing products after they are approved by the WHO. According to the report, the revised stance is intended to help potential acquirers move forward with discussions, as WHO approval for vaccines is due in a few weeks.
In early August, the WHO requested mpox vaccine makers submit the relevant data so as to speed up its reviews and grant a potential emergency nod by mid-September. The organization has already declared the ongoing mpox outbreak centered on Africa a global health emergency. Listed manufacturers of mpox vaccines include Bavarian Nordic ( OTCPK:BVNRY ) ( OTCPK:BVNKF ).
On Wednesday, the Danish biotech raised its 2024 outlook after receiving an order to supply 440K doses of its mpox vaccine to an undisclosed European country. Emergent BioSolutions' ( NYSE: EBS ) ACAM2000 vaccine, approved for smallpox, is currently under FDA review as a mode of immunization against the mpox virus. The company has also responded to the WHO's request for information for a potential emergency listing.
More on Bavarian Nordic Bavarian Nordic A/S (BVNKF) Q2 2024 Earnings Call Transcript Mpox Stocks Have Popped, But Pickings Are Slim For The Discerning Investor Bavarian Nordic: Jynneos Expansion Amid Global Health Emergencies Bavarian Nordic A/S reports 1H results Mpox stocks in focus as Thailand reports first case in Asia linked to new strain.
